Intravenous golimumab and infliximab are both widely used in the treatment of rheumatoid arthritis (RA) in the United States, though these anti–tumor necrosis factor agents have markedly different dosing recommendations; patients who receive golimumab may receive 7 infusions during year 1, while patients who receive infliximab may receive between 8 and 14 infusions during year 1.
Intravenous golimumab and infliximab are both widely used in the treatment of rheumatoid arthritis (RA) in the United States, though these anti—tumor necrosis factor agents have markedly different dosing recommendations; patients who receive golimumab may receive 7 infusions during year 1, while patients who receive infliximab may receive between 8 and 14 infusions during year 1.
A recent study evaluated treatment patterns and infusion-related healthcare expenditures from a commercial payer perspective for matched RA cohorts starting each of the 2 drugs, and it found that golimumab saves on costs in RA relative to infliximab.
The retrospective, observational cohort study used administrative healthcare claims data from the MarketScan database. The matched golimumab and infliximab cohorts each contained 547 patients with RA who were initiating therapy. In a mean followup of 609 days (standard deviation [SD], 161 days), the mean treatment duration was 396 days (SD, 240 days) for the golimumab group and 397 days (SD, 239 days) for the infliximab group.
A total of 3961 golimumab and 4716 infliximab infusions were administered. The golimumab group received significantly fewer infusions compared with the infliximab group; the mean number of induction plus maintenance infusions per patient was 7.2 (SD, 4.3) for golimumab versus 8.6 (SD, 5.6) for infliximab (P = .018).
All claims were associated with billed infusion time; fewer than 1% of golimumab infusions, versus 96% of infliximab infusions, had claims for more than 1 hour of billed infusion time.
The total mean drug cost per infusion of golimumab was $5622 (SD, $3641) versus $5083 (SD, $4339) for infliximab. The mean administration cost per infusion was $224 (SD, $151) versus $360 (SD, $281), for the 2 treatments, respectively.
Estimated total costs per patient for the first year of therapy (based on real-world dosing and administration data, weighted maintenance infusion intervals, and commercial costs) were $41,104 for golimumab versus $51,611 for infliximab.
Furthermore, write the authors, while biosimilar infliximab was not present in the data set, “given the assumption that biosimilar [infliximab] would likely demonstrate similar dosing and administration patterns to originator [infliximab], we were able to confirm that [golimumab] treatment patterns observed in this study would be cost saving over biosimilar [infliximab] under commercial reimbursement scenarios.”
The study was funded by Janssen.
Reference
Ellis LA, Malangone-Monaco E, Varker H, et al. Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. Clinicoecon Outcomes Res. 2019;11:99-110. doi: 10.2147/CEOR.S185547.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.